ѻýҕl

Hand Motions Predict Memory Impairment; APOE4 Smell Loss; Alzheimer's Drug Guidance

<ѻýҕl class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Neuro Break over a computer rendering of neurons.

Hand motor tests predicted in a study of nearly 1,200 older adults without cognitive symptoms. (Alzheimer's & Dementia)

Investigational compared with placebo in a phase II trial of GBA1-associated Parkinson's disease. (Lancet Neurology)

Tickling rats, then measuring their squeaks and brain activity, showed that the for play. (Neuron)

People who carried the Alzheimer's risk allele APOE4 appeared to before losing odor identification or cognitive function. (Neurology)

Atogepant (Qulipta) showed benefit over placebo in in a phase III trial. (The Lancet)

The American Academy of Neurology offered about anti-amyloid monoclonal antibodies like lecanemab (Leqembi) to treat early Alzheimer's disease. (Neurology)

The odds of receiving a for radicular low back pain were less with chiropractic spinal manipulation than usual care, a retrospective U.S. study showed. (BMJ Open)

An cerebrospinal fluid profile appeared to be benign, despite being classified as a pathologic change by Alzheimer's disease guidelines. (JAMA Neurology)

Both the number and volume of were associated with future accumulation of disability, largely independent of relapses. (Journal of Neurology, Neurosurgery & Psychiatry)

Biogen agreed to , maker of omaveloxolone (Skyclarys), which was approved this year to treat Friedreich's ataxia.

  • Judy George covers neurology and neuroscience news for ѻýҕl, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.